Analysis of new growth promoting black market products

A number of unknown pharmaceutical preparations seized by Danish customs authorities were submitted for liquid chromatography-high resolution mass spectrometry (LC-HRMS) analysis. Comparison with reference standards unequivocally identified the content of the powders as analogs of the growth hormone secretagogues GHRP-2 (Pralmorelin), GHRP-6, Ipamorelin, and modified growth hormone releasing factor (modified GRF 1-29), which can be used as performance-enhancing substances in sports. In all cases, the detected modification involved the addition of an extra glycine amino acid at the N-terminus, and analytical methods targeting growth hormone secretagogues should hence be updated accordingly.

Section: Resultssupporting

confidence: 70%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Glycine‐modified growth hormone secretagogues identified in seized doping material

Gajda

Holm

Hoej

et al. 2018

“…Modifications of illicit peptidic drugs, mostly by N ‐terminally added amino acid residues, have been reported also for the growth hormone releasing peptide (GHRP)‐2, GHRP‐6, and ipamorelin . Until the metabolism of these compounds is clarified, the structural alteration needs to be taken into consideration in routine doping control test methods, such as the multi‐analyte procedure presented by Cuervo et al A total of 15 peptidic drugs prohibited in sports, including GHRPs 1, 2, 4, 5, and 6 as well as relevant metabolites and alexamorelin, hexarelin, anamorelin, and ipamorelin were determined from 1 mL of urine.…”

Section: Peptide Hormones Growth Factors Related Substances and MImentioning

confidence: 99%

“…In addition, next‐generation multi‐analyte test methods are featured, which have continued to represent preferred options for initial sample testing. Data obtained from confiscated products have necessitated increased vigilance concerning modified doping agents arguably designed to support the evasion of doped athletes …”

Section: Introductionmentioning

confidence: 99%

Annual banned‐substance review: Analytical approaches in human sports drug testing

Thevis

Kuuranne

Geyer

2019

Self Cite

A number of high profile revelations concerning anti‐doping rule violations over the past 12 months have outlined the importance of tackling prevailing challenges and reducing the limitations of the current anti‐doping system. At this time, the necessity to enhance, expand, and improve analytical test methods in response to the substances outlined in the World Anti‐Doping Agency (WADA) Prohibited List represents an increasingly crucial task for modern sports drug testing programs. The ability to improve analytical testing methods often relies on the expedient application of novel information regarding superior target analytes for sports drug testing assays, drug elimination profiles, and alternative sample matrices, together with recent advances in instrumental developments. This annual banned‐substance review evaluates literature published between October 2017 and September 2018 offering an in‐depth evaluation of developments in these arenas and their potential application to substances reported in WADA's 2018 Prohibited List.

Screening and confirmatory analysis of recombinant human erythropoietin for racing camels' doping control

Delcourt¹,

Garcia²,

Chabot³

et al. 2020

Recombinant human erythropoietin (rHuEPO) belongs to the therapeutic class of erythropoiesis stimulating agents (ESAs) due to its implication in the creation pathway of red blood cells and thus enhancement of oxygenation. Because of this bioactivity, rHuEPO has been considered as a major doping agent in sports competitions for decades. Over the years, doping control laboratories designed several analytical strategies applied to human and animal samples to highlight any misuse. Even though multiple analytical approaches have been reported, none has yet been dedicated to racing camels. Here, we describe an analytical strategy to test camel plasma samples at screening using an ELISA assay and a targeted nano‐liquid chromatography–high‐resolution tandem mass spectrometry for confirmatory analysis. The method was validated and has been successfully applied to post‐race samples, allowing the detection of a positive case of rHuEPO administration.